Overview
Investment firm advancing transformative biomedical innovations.
Founded
2017
Deals · 12mo
5
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
InduPro | Aug 2026Participated | $77 MSeries B | |
ADCendo | Apr 2026Participated | $76 MSeries C | |
Poplar Therapeutics | Mar 2026Participated | $45 MSeries A | |
Poplar Therapeutics | Jan 2026Led | $50 MSeries A | |
Protego Biopharma | Dec 2025Participated | $130 MSeries B | |
Antares Therapeutics | Jun 2025Participated | $177 MSeries A | |
Attovia Therapeutics | Apr 2025Participated | $90 MSeries C | |
Candid Therapeutics | Sep 2024Participated | $370 MOther Equity | |
Halda Therapeutics | Aug 2024Participated | $126 MSeries B | |
Third Arc Bio | Jul 2024Led | $165 MSeries A | |
Scorpion Therapeutics | Jul 2024Participated | $150 MSeries C | |
Alterome Therapeutics | Apr 2024Participated | $132 MSeries B | |
InduPro | Aug 2026Participated | $77 MSeries B | |
ADCendo | Apr 2026Participated | $76 MSeries C | |
Poplar Therapeutics | Mar 2026Participated | $45 MSeries A | |
Poplar Therapeutics | Jan 2026Led | $50 MSeries A | |
Protego Biopharma | Dec 2025Participated | $130 MSeries B | |
Antares Therapeutics | Jun 2025Participated | $177 MSeries A | |
Attovia Therapeutics | Apr 2025Participated | $90 MSeries C | |
Candid Therapeutics | Sep 2024Participated | $370 MOther Equity | |
Halda Therapeutics | Aug 2024Participated | $126 MSeries B | |
Third Arc Bio | Jul 2024Led | $165 MSeries A | |
Scorpion Therapeutics | Jul 2024Participated | $150 MSeries C | |
Alterome Therapeutics | Apr 2024Participated | $132 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 2 |
| Series A | 11 | 9 |
| Series B | 3 | 13 |
| Series C+ | 2 | 9 |
| Other Equity | 3 | 4 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 1 |
| Jun '18 | 0 |
| Jul '18 | 1 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 3 |
| Mar '19 | 0 |
| Apr '19 | 1 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 1 |
| Nov '19 | 1 |
| Dec '19 | 1 |
| Jan '20 | 2 |
| Feb '20 | 0 |
| Mar '20 | 1 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 1 |
| Aug '20 | 2 |
| Sep '20 | 1 |
| Oct '20 | 3 |
| Nov '20 | 0 |
| Dec '20 | 2 |
| Jan '21 | 2 |
| Feb '21 | 1 |
| Mar '21 | 1 |
| Apr '21 | 2 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 2 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 2 |
| Feb '22 | 0 |
| Mar '22 | 1 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 1 |
| Sep '23 | 2 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 2 |
| Aug '24 | 1 |
| Sep '24 | 1 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 1 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 57 |
| Manufacturing | 2 |
| Space & Frontier Tech | 2 |
| Networks, Cloud & Communication | 1 |
| E-Commerce & Retail | 1 |
| Professional Services | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 0 |
| $10M-$25M | 2 |
| $25M-$50M | 4 |
| $50M-$100M | 27 |
| $100M-$250M | 19 |
| $250M-$500M | 4 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 53 |
| Europe | 3 |
| India | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| OrbiMed | 16 |
| EcoR1 Capital | 11 |
| Logos Capital | 11 |
| Surveyor Capital | 11 |
| Nextech Invest | 10 |
| Boxer Capital | 9 |
| Invus | 8 |
| Omega Funds | 8 |
| MPM Capital | 7 |
| Polaris Partners | 7 |
| RA Capital Management | 7 |
| Atlas Venture | 6 |
| BVF Partners | 6 |
| Cormorant Asset Management | 6 |
| Wellington Management | 6 |
| Eventide Asset Management | 5 |
| Foresite Capital | 5 |
| Janus Henderson Investors | 5 |
| Samsara BioCapital | 5 |
| Venrock | 5 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 20 | 35% |
| Participating | 37 | 65% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 15% |
| Co-led | 17 | 85% |
Team
Co-Founder & Senior Managing Director
Co-Founder and Managing Director
Co-Founder & Sr. Managing Director
Senior Managing Director
COO and CFO
Co-Founder
Associate
Co-Founder & Managing Director